{
  "@context": {
    "dcterms": "http://purl.org/dc/terms/",
    "cito": "http://purl.org/spar/cito/",
    "deo": "http://purl.org/spar/deo/"
  },
  "@id": "https://hypothesis.bioagent.ai/ry5n8khin4",
  "@type": "deo:FutureWork",
  "cito:usesDataFrom": [
    "https://doi.org/10.1186/s13041-024-01028-8",
    "https://doi.org/10.1371/journal.pone.0172640",
    "https://doi.org/10.1002/dad2.12391",
    "https://doi.org/10.1038/s41586-023-06801-2"
  ],
  "dcterms:references": [
    "# Mechanistic Hypothesis Connecting DOPAL's Anti-Oligomerization Effect and Carbidopa's Lack of Effect on Aβ Processing\n\n## 1. Background\nDOPAL (3,4-dihydroxyphenylacetaldehyde), a reactive aldehyde produced during dopamine metabolism via monoamine oxidase (MAO), has been demonstrated to decrease Aβ oligomerization in human neuroblastoma cells, thereby reducing the cytotoxic effects of aggregated Aβ. As shown in Abstract 1, L-DOPA administration significantly reduces Aβ plaque number in 5xFAD mice through upregulation of degradation enzymes like NEP and ADAM17. Paradoxically, Abstract 2 indicates that L-DOPA and dopamine agonists can enhance Aβ generation and γ-secretase activity through dopamine D2 receptor-mediated β-arrestin 2 signaling, suggesting complex, potentially opposing effects of dopaminergic pathways on Aβ processing.\n\n## 2. Knowledge Gap\nThe molecular mechanisms reconciling how dopamine metabolism (via DOPAL) can inhibit Aβ oligomerization while dopamine signaling may simultaneously increase Aβ generation remain undefined. Moreover, it's unclear why Carbidopa, which prevents peripheral conversion of L-DOPA to dopamine but has minimal brain penetration, shows no effect on Aβ generation despite the established connections between dopaminergic pathways and amyloid processing.\n\n## 3. Central Hypothesis\nDOPAL mediates a subcellular compartment-specific dual mechanism of Aβ processing wherein it both enhances lysosomal targeting of monomeric Aβ through protein carbonylation and competitively inhibits γ-secretase activity when localized to lipid rafts, effects that operate independently of peripheral dopamine metabolism targeted by Carbidopa.\n\n## 4. Proposed Mechanism\n1. Dopamine undergoes MAO-mediated oxidation to produce DOPAL preferentially within specific neuronal subcellular compartments, particularly in lipid rafts where both APP processing and Aβ oligomerization are concentrated.\n\n2. Within these microdomains, DOPAL's reactive aldehyde group forms Schiff base adducts with lysine residues in the Aβ peptide, modifying its structure to prevent β-sheet formation necessary for oligomerization while simultaneously creating a molecular \"tag\" recognized by autophagy adaptor proteins.\n\n3. DOPAL-modified Aβ monomers are preferentially targeted to the autophagy-lysosomal pathway via p62/SQSTM1 recognition of carbonylated proteins, increasing their degradation rate before oligomerization can occur.\n\n4. Concurrently, DOPAL directly interacts with the γ-secretase complex within lipid rafts, allosterically modifying its conformation to reduce its enzymatic efficiency when β-arrestin 2 signaling would otherwise enhance its activity following D2 receptor activation.\n\n5. This dual mechanism creates a homeostatic feedback loop wherein increased dopamine signaling (which promotes Aβ generation via D2R-β-arrestin 2) simultaneously increases DOPAL production, which then both inhibits further Aβ generation and prevents oligomerization of existing Aβ peptides.\n\n## 5. Testable Predictions\n1. Selective inhibition of MAO-B in neuronal cultures should decrease DOPAL levels and consequently increase both γ-secretase activity and Aβ oligomerization, effects that would be rescued by exogenous DOPAL application specifically in lipid raft-enriched membrane fractions.\n\n2. DOPAL-modified Aβ peptides should show increased co-localization with autophagy markers (LC3, p62) compared to unmodified Aβ, and cells with impaired autophagy (ATG5/7 knockdown) should show diminished protective effects of DOPAL against Aβ toxicity.\n\n3. In transgenic AD mouse models, increased DOPAL levels (achieved through selective ALDH inhibition to slow DOPAL metabolism) should result in both decreased γ-secretase activity within lipid rafts and increased autophagy-dependent clearance of monomeric Aβ, leading to reduced plaque pathology despite unchanged or even increased total Aβ production.\n\n## 6. Potential Experimental Approaches\n1. Develop a cell-based system using fluorescently-tagged Aβ peptides in conjunction with subcellular compartment markers and live-cell imaging to track the spatiotemporal dynamics of DOPAL-Aβ interactions. This could be complemented by membrane fractionation studies to isolate lipid rafts and analyze the effect of DOPAL on γ-secretase localization and activity within these microdomains compared to non-raft membranes.\n\n2. Generate transgenic mice with neuron-specific upregulation of MAO-B to increase DOPAL production, crossed with AD mouse models, to examine: (1) lipid raft-associated changes in γ-secretase activity, (2) rates of autophagy-mediated Aβ clearance, and (3) Aβ oligomerization patterns in vivo. These models could be used to test the efficacy of manipulating DOPAL levels through pharmacological approaches alongside treatments that affect dopamine signaling pathways.\n\nThis hypothesis provides a novel mechanistic framework explaining why the anti-oligomerization effects of DOPAL occur despite D2R signaling-mediated increases in Aβ generation, and why Carbidopa's peripheral inhibition of dopamine synthesis would not impact these central nervous system-specific processes. It also suggests new therapeutic approaches focused on modulating DOPAL levels in specific subcellular compartments rather than broadly affecting dopamine signaling."
  ],
  "dcterms:subject": [
    "amyloid beta",
    "neurodegenerative disease"
  ],
  "dcterms:source": [
    "DOPAL, a dopamine metabolite, decreases Aβ oligomerization in human neuroblastoma cells, reducing the cytotoxic effects of Aβ.",
    "Carbidopa showed little to no effect on amyloid-β generation in neuronal cells when tested alongside other anti-Parkinson's medications."
  ],
  "dcterms:abstract": [
    "Dopamine plays important roles in cognitive function and inflammation and therefore is involved in the pathogenesis of neurodegenerative diseases, including Alzheimer's disease (AD). Drugs that increase or maintain dopamine levels in the brain could be a therapeutic strategy for AD. However, the effects of dopamine and its precursor levodopa (L‑DOPA) on Aβ/tau pathology in vivo and the underlying molecular mechanisms have not been studied in detail. Here, we investigated whether L‑DOPA treatment alters neuroinflammation, Aβ pathology, and tau phosphorylation in 5xFAD mice, a model of AD. We found that L‑DOPA administration significantly reduced microgliosis and astrogliosis in 5xFAD mice. In addition, L‑DOPA treatment significantly decreased Aβ plaque number by upregulating NEP and ADAM17 levels in 5xFAD mice. However, L‑DOPA‑treated 5xFAD mice did not exhibit changes in tau hyperphos‑phorylation or tau kinase levels. These data suggest that L‑DOPA alleviates neuroinflammatory responses and Aβ pathology but not tau pathology in this mouse model of AD.",
    "Although levodopa is the first-line medication for the treatment of Parkinson's disease (PD) showing unsurpassable efficiency, its chronic use causes dyskinesia. Accordingly, dopamine agonists are increasingly employed as monotherapy or in combination with levodopa to reduce the risk of motor complications. It is well recognized that patients with PD often exhibit cognitive deficits. However, clinical and animal studies assessing the effects of dopaminergic medications on cognition are controversial. Amyloid-β (Aβ) is one of the major hallmarks of Alzheimer's disease (AD), leading to progressive memory loss and cognitive deficit. Interestingly, the abnormal accumulation of Aβ is also detected in PD patients with cognitive deficits. Evidence indicated that levodopa induced a mild increase of Aβ plaque number and size in the brain of AD mouse. However, the underlying mechanism is unclear. Here we present that both levodopa and piribedil enhance the generation of Aβ and the activity of γ-secretase in human neuronal cells and primary neurons isolated from AD mouse. This effect was reduced by either the antagonism or the knockdown of dopamine D2 receptor (D2R). We further showed that in the cells expressing β-arrestin 2-biased D2R mutant, piribedil promoted cellular Aβ production to the extent comparable to the wild-type D2R whereas this activity was absent in those with G protein-biased D2R mutant. Moreover, the knockdown of β-arrestin 2 attenuated the increases of Aβ generation and γ-secretase activity mediated by levodopa or piribedil. Thus, our study suggests that targeting D2R-mediated β-arrestin function may have potential risk in the modulation of Aβ pathology.",
    "[18F]AZD4694 is an amyloid beta (Aβ) imaging agent used in several observational studies and clinical trials. This study assessed 146 individuals evaluated with [18F]AZD4694 at baseline and a 2‐year follow‐up, revealing longitudinal patterns of Aβ accumulation. Results showed that cognitively unimpaired older adults displayed subtle Aβ accumulation, while Aβ positive cases exhibited greater increases, underscoring the agent’s potential to monitor Aβ levels in clinical settings.",
    "Frontotemporal lobar degeneration (FTLD) causes frontotemporal dementia (FTD), the most common form of dementia after Alzheimer’s disease, and is often also associated with motor disorders. In this study, we used cryogenic electron microscopy (cryo-EM) to determine the structures of amyloid filaments in FTLD–FET, revealing the presence of TAF15 amyloid filaments, establishing TAF15 proteinopathy as significant in neurodegenerative disease."
  ]
}